Brent Egan to Platelet Aggregation Inhibitors
This is a "connection" page, showing publications Brent Egan has written about Platelet Aggregation Inhibitors.
Connection Strength
0.372
-
Relationship between 'on-treatment platelet reactivity', shear stress, and micro-embolic signals in asymptomatic and symptomatic carotid stenosis. J Neurol. 2020 Jan; 267(1):168-184.
Score: 0.149
-
Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke. J Neurol. 2014 Jul; 261(7):1405-12.
Score: 0.102
-
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. J Neurol Sci. 2022 10 15; 441:120334.
Score: 0.045
-
Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes. J Neurol Sci. 2017 Apr 15; 375:404-410.
Score: 0.031
-
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke. J Neurol. 2013 Feb; 260(2):590-6.
Score: 0.023
-
Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci. 2005 Jun; 329(6):292-305.
Score: 0.014
-
Management and outcome of acute myocardial infarction in older patients in the thrombolytic era. J Am Geriatr Soc. 1999 Mar; 47(3):291-4.
Score: 0.009